TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02713451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.
Study: NCT01322906

Intervention type: OTHER
Group type: OTHER
Intervention: Group 1
Description: Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).

Intervention type: OTHER
Group type: OTHER
Intervention: Group 2
Description: Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).

Intervention type: OTHER
Group type: OTHER
Intervention: Group 3
Description: Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
Study: NCT02407626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous anesthesia is a clinical standard procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Volatile anesthesia is a clinical standard procedure
Study: NCT01511445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF) with PEEK Cage
Description: Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage
Description: Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
Study: NCT00709202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betahistine
Description: Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT03069586

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No pulmonary recruitment
Description: At the end of surgery no intervention was completed
Study: NCT01681745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch III
Study: NCT01840735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5737

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01739101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Plan
Description: A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
Study: NCT02903004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated Liposomal Doxorubicin

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine

Intervention type: DRUG
Group type: OTHER
Intervention: Weekly Paclitaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Study: NCT02500537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology
Description: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
Study: NCT04717206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyomtric training to female badmninton players
Description: Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills.
Study: NCT03266679

Intervention type: OTHER
Group type: OTHER
Intervention: Metacognitive Reflection and Insight Therapy - Adapted
Description: The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
Study: NCT05451420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN α- 2b
Description: Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN α- 2b
Description: Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）
Study: NCT01273974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intradermal influenza vaccine
Description: 0.25ml ,intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular influenza vaccine
Description: 0.5ml,intramuscular
Study: NCT03134222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 30 mg tablets administered orally once daily with or without food
Study: NCT00914693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Study: NCT00284830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Pulse Generators
Description: dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
Study: NCT05253456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Derma -Dartos Flap for second layer closure
Description: usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
Study: NCT02920125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUVED
Description: Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: REIMMUGEN
Description: Whole Cow colostrum in powder put in capsules; 300mg each

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grain flour placebo
Description: Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
Study: NCT03379519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain Attention Training (MAT)
Description: The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive information activities (PIA)
Description: The active control group (Passive information activities) training content included reading online e-books and playing online games.
Study: NCT00372892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 per week for 4 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline IV placebo once per week for 4 consecutive weeks
Study: NCT00045942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole was commercially available.
Study: NCT01449890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-mail follow up care
Description: After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
Study: NCT03679403

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
Study: NCT00045942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole was commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
Study: NCT03679403

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
Study: NCT00559689

Intervention type: DRUG
Intervention: Budesonide,hydrofluoroalkane-beclomethasone dipropionate
Description: receive twice-daily administration

Intervention type: DRUG
Intervention: Budesonide,hydrofluoroalkane-beclomethasone
Description: once-daily administration at bedtime
Study: NCT04156321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa fry
Description: School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm .
Study: NCT00570245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: inhalation, 10 ppm, for up to 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
Study: NCT00277758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (\> 85 kg)
Study: NCT03134222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 30 mg tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanraplenib placebo
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib placebo
Description: Tablets administered orally once daily with or without food
Study: NCT00277758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (\> 85 kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha
Description: Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
Study: NCT03134222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Tablets administered orally once daily with or without food
Study: NCT03645785

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal fluid intake without true lemon
Description: 16.9oz water with True Lemon

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double fluid intake plus 3 bottles of water with True Lemon
Description: No intervention
Study: NCT00322166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunlight
Description: Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunlight and calcium
Description: Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
Study: NCT00520234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: 50 mg IV daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 100 cc IV daily
Study: NCT00277758

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon Alpha
Description: Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inteleukin-2
Description: Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
Study: NCT02443961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell (MSC) therapy
Description: 3 doses of 5 million MSC will be administered
Study: NCT00277758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin + Pegylated interferon-alpha
Description: Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight \<65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight \>85 kg.
Study: NCT00849589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized screening and brief physician advice
Description: Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized SBA with technological extenders
Description: Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
Study: NCT02866422

Intervention type: OTHER
Intervention: No Intervention
Description: Observational Study: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: Observational Study: No intervention
Study: NCT00436163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg subcutaneously once per week for 48 weeks.
Study: NCT01061281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis MF IOL
Description: 20 patients enrolled with the Tecnis MF IOL.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalens AO IOL
Description: 20 patients enrolled with the Crystalens AO
Study: NCT02620891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: helium oxygen mixture
Study: NCT00397488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study: NCT04566848

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Measuring the sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 levels with flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Measuring the sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 levels with flow cytometry
Study: NCT03193177

Intervention type: OTHER
Intervention: the 21-day fasting-like diet
Description: a fasting-like diet with 400 KJ energy intake per day for 21 days
Study: NCT01764347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo robotic radical prostatectomy
Study: NCT01962779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
Study: NCT02229773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study: NCT01764347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided prostate biopsy
Description: Undergo MRI-TRUS fusion image-guided prostate biopsy
Study: NCT02229773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS high dose
Study: NCT01764347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI-TRUS fusion image-guided prostate biopsy
Study: NCT02089997

Intervention type: DRUG
Intervention: Sodium Risedronate
Description: Sodium risedronate tablets
Study: NCT00665145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: Active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: Active drug
Study: NCT03554577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_A
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_B
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_C
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.
Study: NCT03415802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and S-1
Description: Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)